Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
UTA2-1-loaded PD-L1/L2-silenced donor dendritic cell vaccination after allogeneic stem cell transplantation
NL-OMON22602Phase 2Not yet recruiting
- Sponsor
- VU University Medical Center
- Start
- Aug 2019
- Modality
- Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies, Vaccines & Immunotherapeutics, Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of UTA2-1 peptide-loaded PD-L1/L2-silenced donor dendritic cells in multiple myeloma (MM), chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), non-Hodgkin lymphoma (NHL) and 1 more, sponsored by VU University Medical Center. Primary endpoints: Toxicity and feasibility, Immune response and 3 more. Planned start Aug 2019; status: not yet recruiting.
02
Drugs
UTA2-1 peptide-loaded PD-L1/L2-silenced donor dendritic cells
03
Conditions
multiple myeloma (MM)chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)non-Hodgkin lymphoma (NHL)acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NL-OMON22602.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON22602.